Judicial Analysis Court Copy Headnote Facts Arguments Court observation

2026 Supreme(Online)(NCLT) 235

NATIONAL COMPANY LAW TRIBUNAL
Prabhat Kumar, Hon’ble Member (Technical), Sushil Mahadeorao Kochey, Hon’ble Member (Judicial)
Venkatraman Narayan Bhagwat – Appellant
Versus
DR. ACHARYA LABORATORIES PRIVATE LIMITED – Respondent
CP 162 of 2022

Advocates:
For the Petitioner: Adv. Shyam Kapadia, Adv. Aliya Tabassum
For the Respondent: Adv. Manorma Mohanty, Adv. Hitanshu Jain

Rights issue diluting minority in quasi-partnership company void if fails proper purpose doctrine—not bona fide need but oppressive, warranting fair value buyout on trust breakdown.

Headnote:(A) Companies Act, 2013 - Sections 241, 242, 244 - Oppression and mismanagement - Quasi-partnership company - Petitioner holding 16% shares diluted to 6.4% through rights issue - Rights issue held invalid for failing proper purpose doctrine as not bona fide for company's needs, evidenced by healthy finances, short subscription time (36 hours), secrecy of allottee (related party), inconsistent purposes stated - Amendments to AoA granting special privileges to majority not set aside but indicative of mala fides; one clause void as contrary to Act - Irretrievable breakdown of trust in quasi-partnership warrants buyout at fair value on pre-issue holding as on 31.3.2022 plus 8% interest till 31.12.2025. (Paras 46, 47, 52)

(B) Companies Act, 2013 - Section 62(1)(a)(iii) - Rights issue - Unsubscribed shares disposal must not be disadvantageous to shareholders/company; cannot be at rights price to third parties without special resolution under Section 62(1)(c). (Para 41)

(C) Companies Act, 2013 - Section 102 - Explanatory statement for special business must disclose deviations from standard Table F and implications to enable informed voting; non-disclosure shows mala fides though amendment not invalidated. (Paras 30, 31)

(D) Companies Act, 2013 - Section 244 - One-fifth or one-tenth member in small company entitled to file petition. Section 433 - 3-year limitation under Limitation Act applies; no delay. (Paras 20, 21) (E) Company law - Quasi-partnership - Pre-existing partnership converted to company retaining profit shares qualifies; superimposition of equitable considerations justified on personal relationship, mutual confidence breakdown. (Paras 48, 50)

Facts of the case:
Petition under Sections 241-242 against acts of oppression including MoA/AoA amendments without proper disclosure, rushed rights issue increasing authorised capital then allotting unsubscribed shares (Petitioner's entitlement) to related party, diluting minority from 16% to 6.4%. Company financially sound with cash reserves, receivables, no urgent need. Historical quasi-partnership from erstwhile firm; exit offers rejected sans valuation. Respondents contested maintainability on delay, threshold, suppression.

Findings of Court:
Petition maintainable; rights issue oppressive, void; AoA amendments mala fide but largely valid; irretrievable trust breakdown; direct buyout of Petitioner's pre-issue shares at fair value as on 31.3.2022 by valuer +8% interest to 31.12.2025 payable in 3 months.

Issues: Validity of rights issue under proper purpose doctrine; sufficiency of explanatory statements; quasi-partnership status; maintainability grounds; oppression via dilution in financially healthy company.

Ratio Decidendi: Rights issue fails proper purpose test if not bona fide for company benefit but to dilute minority, supported by financials, timelines, secrecy; quasi-partnerships attract equitable buyout on trust breakdown avoiding winding up prejudice.

Result: Company Petition allowed; buyout ordered.

Table of Content
1. petition under sections 241-244 alleging oppression and mismanagement. (Para 1 , 2 , 3 , 4)
2. company originated as quasi-partnership from prior partnership firm. (Para 5 , 6 , 7 , 8)
3. petitioner's trust enabled majority decisions without scrutiny. (Para 9 , 10 , 11)
4. rights issue conducted with inadequate notice and short subscription period. (Para 12 , 13)
5. moa/aoa amendments without notice, entrenching majority control. (Para 14 , 15)
6. suspected non-arm's length related party transactions. (Para 16)
7. respondents challenge petition maintainability and allegations. (Para 17)
8. petition maintainable; no delay, threshold met, no suppression. (Para 18 , 19 , 20 , 21 , 22 , 23 , 24)
9. no evidence of exit offers; no adverse inference. (Para 25)
10. aoa amendments defective in disclosure but not set aside; indicates mala fides. (Para 26 , 27 , 28 , 29 , 30 , 31 , 32)
11. moa capital increase valid; examine with rights issue for oppression. (Para 33 , 34 , 35)
12. rights issue procedurally flawed with secretive allotment to related entity. (Para 36 , 37 , 38 , 39 , 40)
13. no genuine fund need; rights issue violated proper purpose doctrine. (Para 41 , 42 , 43)
14. rights issue oppressive under proper purpose and mala fide tests. (Para 44 , 45 , 46 , 47)
15. quasi-partnership confirmed; irretrievable breakdown justifies buyout. (Para 48 , 49 , 50 , 51 , 52)
16. petition allowed; order share buyout at fair value. (Para 53)

ORDER

1. The Petition CP 162 of 2022 is filed on 27.3.2022 by Mr. Venkatraman Narayan Bhagwat (“Petitioner”) against the alleged acts of oppression and mis- management committed by Respondent No. 2 to 5 in the affairs of M/s Dr. Acharya Laboratories Private Ltd. (Respondent No. 1) seeking following reliefs in terms of Section 241-242 of the Companies Act, 2013:

i. Declare that the business/ affairs of the Respondent No.1 Company are being carried out by the Respondents No. 2 to 5 in a manner highly prejudicial to the interest of the Respondent No.1 Company, its members, its creditors, its employees, its minority directors, and the public at large and in a manner that is oppressive to the Respondent No. 1 Company and to its members including the Petitioner;

ii. Declare that the Respondents No.2 to 5 have brought about a material change in the management or control of the company, and that by reason of such change, the affairs of the company are being, and it is that such affairs will be conducted in a manner prejudicial to the interest of the Respondent No.1 Company and its members including its minority shareholders and directors such as the Petitioner. Direct an enquiry be conducted into the affairs of the Respondent No. 1 Company;

iii. Declare that the entire rights issue of 15,00,000 shares of INR 10 each aggregating to INR 1,50,00,000 including but not limited to the notices in connection with the board meetings dated 10.03.2022 and 17.03.2022 resolutions passed in the board meetings dated 12.03.2022 and 20.03.2022 notice of rights issue dated 13.03.2022, and allotment of shares pursuant thereto are null and void;

iv. Pass an order of permanent injunction against the Respondents from acting in furtherance of the said rights issue of 15,00,000 shares of INR 10 each, aggregating to INR 1,50,00,000 including the documents mentioned in para (iv) above, and in particular from giving effect, in any manner, to any allotment purported to have been made pursuant thereto;

v. Declare that all alterations of the Respondent No. 1 company's MoA and AoA, for which the Petitioner did not receive any notice, is unlawful and non-est;

vi. Pass an order for impartial, true and fair valuation of the of the Respondent No. 1 Company by a registered independent valuer in accordance with Section 247 of the Act read with the Companies (Registered Valuers and Valuation) Rules, 2017; and/ or vii. any other Order, which, in the opinion of this Hon'ble Tribunal, is just and equitable in the circumstances of the present case.

2. The R

Click Here to Read the rest of this document

2026 Supreme(Online)(NCLT) 235

NATIONAL COMPANY LAW TRIBUNALPrabhat Kumar, Hon’ble Member (Technical), Sushil Mahadeorao Kochey, Hon’ble Member (Judicial)Venkatraman Narayan Bhagwat – AppellantVersusDR. ACHARYA LABORATORIES PRIVATE LIMITED – RespondentCP 162 of 2022

Rights issue diluting minority in quasi-partnership company void if fails proper purpose doctrine—not bona fide need but oppressive, warranting fair value buyout on trust breakdown.

Cases Referred (2)

NATIONAL COMPANY LAW TRIBUNAL
Prabhat Kumar, Hon’ble Member (Technical), Sushil Mahadeorao Kochey, Hon’ble Member (Judicial)
Venkatraman Narayan Bhagwat – Appellant
Versus
DR. ACHARYA LABORATORIES PRIVATE LIMITED – Respondent
CP 162 of 2022